insitro Hires AI and Machine Learning Visionary, Emily Fox, Ph.D., as Senior Vice President of AI/ML
Leading Clinical Research Innovator, Amy Abernethy, M.D., Ph.D., Joins insitro Board of Directors
Insitro Hires CMO to Advance Therapeutic Programs Toward the Clinic
insitro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a machine learning-powered drug discovery and development company, today announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a 24-year career at Amgen, where he has led the organization's research platforms for over a decade as vice president, research - therapeutic discovery.
insitro Appoints Philip Tagari, Industry-Leading Scientist and Drug Hunter, as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a machine learning-driven drug discovery and development company, today announced the formation of a scientific advisory board (SAB) composed of industry leaders in their respective focus areas. insitro’s SAB brings broad expertise across gene editing, genetics and genomics, machine learning, molecular design and liver and central nervous system diseases. SAB members will work closely with the insitro team to provide insights and guidance into the advancement of insitro’s technologies and development programs.
SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--insitro, a machine learning-driven drug discovery and development company, and Genomics England today announced a collaboration to bring insitro’s machine learning powered embedding search capabilities to Genomic England’s multimodal phenotypic and genetic database. Since it was established in 2013 to deliver the 100,000 Genomes Project, Genomics England has built an unparalleled resource of almost 150,000 whole genomes with corresponding phenotypic data from NHS patients with rare diseases and their families, as well as patients with cancer. Included in this resource, Genomics England has a growing corpus of multimodal and high-dimensional data, including genetic data and histopathology images from its cohort of cancer patients.
insitro, a machine learning-driven drug discovery and development company, today announced that Tom Stocky has been appointed as vice president of product. Mr. Stocky has spent the majority of his career working in technology, including at Facebook, Google, and most recently in a technology-focused role at Denali Therapeutics. In his role at insitro, he will lead product strategy, planning, and user experience for insitro’s data systems and software tools.
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--insitro, a machine learning-driven drug discovery and development company, today announced that it has raised $400 million in a Series C financing. The financing was led by Canada Pension Plan Investment Board (CPP Investments), with significant participation from current investors Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., Casdin Capital, and funds and accounts managed by BlackRock as well as ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital and Alexandria Venture Investments. Also joining in the round are Temasek, Softbank Investment Advisors, an undisclosed leading global investment group, and an undisclosed market-leading payer provider health system in the United States. As part of this financing, Paul McCracken, Ph.D., Senior Portfolio Manager, Thematic Investing, at CPP Investments, will join insitro’s board of directors at the time of the financing’s closing.